The BIOSTAT‐CHF study was designed to address ACEi/ARB and beta‐blocker up‐titration, thus these data may not be suitable for accounting for mineralocorticoid receptor antagonist prescription or treatment dose. This evidence concerns the gene NR3C2 and congestive heart failure.